UNIVERSITAT DE BARCELONA

Efecto del síndrome metabólico provocado por una dieta rica en grasa en ratones APPswe/PS1dE9, modelo experimental de la enfermedad de Alzheimer, y posibles terapias farmacológicas

Miren Ettcheto Arriola

BIBILIOGRAFÍA

BIBLIOGRAFÍA

A

Alafuzoff, I., Overmyer, M., Helisalmi, S., & Soininen, H. (2000). Lower Counts of Astroglia and Activated Microglia in Patients with Alzheimer's Disease with Regular Use of Non-Steroidal Anti-Inflammatory Drugs. *Journal of Alzheimer's Disease: E 2*(1), 37–46.

Alberti, K. G. M. M., & Zimmet, P. Z. (1998). Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus. Provisional report of a WHO Consultation. *Diabetic Medicine*, *15*(7), 539–553.

Albin, R. L., & Greenamyre, J. T. (1992). Alternative excitotoxic hypotheses. *Neurology*, *42*(4), 733–8.

Ali, M. A., El-Abhar, H. S., Kamel, M. A., & Attia, A. S. (2015). Antidiabetic Effect of Galantamine: Novel Effect for a Known Centrally Acting Drug. *PloS One*, *10*(8), e0134648.

Alley, G. M., Bailey, J. A., Chen, D., Ray, B., Puli, L. K., Tanila, H., … Lahiri, D. K. (2010). Memantine lowers amyloid-beta peptide levels in neuronal cultures and in APP/PS1 transgenic mice. *Journal of Neuroscience Research*, *88*(1), 143–54.

Alzheimer´s association. (2014) Alzheimer's disease facts and figures. *Alzheimer's Dementia,* 10(2):e47–92. Recuperado de http://*linkinghub*.elsevier.com/retrieve/pii/S1552526014000624

Arriagada, P. V *et al.* (1992) 'Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease.', *Neurology*, 42(3 Pt 1), pp. 631–9.

Arrieta-Cruz, I., & Gutiérrez-Juárez, R. (2016). The role of insulin resistance and glucose metabolism dysregulation in the development of Alzheimer's disease. *Revista de Investigacion Clinica*, *68*(2), 53–58.

Arrieta-Cruz, I., Knight, C. M., & Gutiérrez-Juárez, R. (2015). Acute Exposure of the Mediobasal Hypothalamus to Amyloid-β25-35 Perturbs Hepatic Glucose Metabolism. *Journal of Alzheimer's Disease*, *46*(4), 843–848.

Arterburn, D. E., Crane, P. K., & Sullivan, S. D. (2004). The coming epidemic of obesity in elderly Americans. *Journal of the American Geriatrics Society*, *52*(11), 1907–12.

Arvanitakis, Z., Wilson, R. S., Bienias, J. L., Evans, D. A., & Bennett, D. A. (2004). Diabetes Mellitus and Risk of Alzheimer Disease and Decline in Cognitive Function. *Archives of Neurology*, *61*(5), 661.

Atamna, H., & Frey, W. H. (2007). Mechanisms of mitochondrial dysfunction and energy deficiency in Alzheimer's disease. *Mitochondrion*, *7*(5), 297–310.

Austin, S., & St-Pierre, J. (2012). PGC1α and mitochondrial metabolism--emerging concepts and relevance in ageing and neurodegenerative disorders. *Journal of Cell Science*, *125*(Pt 21), 4963–71.

Awad, N., Gagnon, M., & Messier, C. (2004). The Relationship between Impaired Glucose Tolerance, Type 2 Diabetes, and Cognitive Function. *Journal of Clinical and Experimental Neuropsychology*, *26*(8), 1044–1080.

B

Banks, W. A. (2006). Denial versus dualism: the blood-brain barrier as an interface of the gut-brain axis. *Endocrinology*, *147*(6), 2609–10.

Banks, W. A., Owen, J. B., & Erickson, M. A. (2012). Insulin in the brain: there and back again. *Pharmacology & Therapeutics*, *136*(1), 82–93.

Banno, R., Zimmer, D., De Jonghe, B. C., Atienza, M., Rak, K., Yang, W., & Bence, K. K. (2010). PTP1B and SHP2 in POMC neurons reciprocally regulate energy balance in mice. *The Journal of Clinical Investigation*, *120*(3), 720–34.

Bartus, R. T., Dean, R. L., Beer, B., & Lippa, A. S. (1982). The cholinergic hypothesis of geriatric memory dysfunction. *Science (New York, N.Y.)*, *217*(4558), 408–14.

Basak, J. M., Verghese, P. B., Yoon, H., Kim, J., & Holtzman, D. M. (2012). Low-density lipoprotein receptor represents an apolipoprotein E-independent pathway of Aβ uptake and degradation by astrocytes. *The Journal of Biological Chemistry*, *287*(17), 13959–71.

Bateman, R. J., Munsell, L. Y., Morris, J. C., Swarm, R., Yarasheski, K. E., & Holtzman, D. M. (2006). Human amyloid-beta synthesis and clearance rates as measured in cerebrospinal fluid in vivo. *Nature Medicine*, *12*(7), 856–61.

Bekris, L. M., Yu, C.-E., Bird, T. D., & Tsuang, D. W. (2010). Genetics of Alzheimer disease. *Journal of Geriatric Psychiatry and Neurology*, *23*(4), 213–27.

Benedict, C., Hallschmid, M., Hatke, A., Schultes, B., Fehm, H. L., Born, J., & Kern, W. (2004). Intranasal insulin improves memory in humans. *Psychoneuroendocrinology*, *29*(10), 1326–34.

Besseiche, A., Riveline, J.-P., Gautier, J.-F., Bréant, B., & Blondeau, B. (2015). Metabolic roles of PGC-1α and its implications for type 2 diabetes. *Diabetes & Metabolism*, *41*(5), 347–357.

Biessels, G. J., Kappelle, A. C., Bravenboer, B., Erkelens, D. W., & Gispen, W. H. (1994). Cerebral function in diabetes mellitus. *Diabetologia*, *37*(7), 643–650.

Birks, J., Grimley Evans, J., Iakovidou, V., & Tsolaki, M. (2000). Rivastigmine for Alzheimer's disease. In J. Birks (Ed.), *Cochrane Database of Systematic Reviews* (p. CD001191). Chichester, UK: John Wiley & Sons, Ltd.

Björkhem, I., & Meaney, S. (2004). Brain cholesterol: long secret life behind a barrier. *Arteriosclerosis, Thrombosis, and Vascular Biology*, *24*(5), 806–15.

Block, M. L., Zecca, L., & Hong, J.-S. (2007). Microglia-mediated neurotoxicity: uncovering the molecular mechanisms. *Nature Reviews Neuroscience*, *8*(1), 57–69.

Bonabello, A., Galmozzi, M. R., Canaparo, R., Isaia, G. C., Serpe, L., Muntoni, E., & Zara, G. P. (2003). Dexibuprofen (S+-isomer ibuprofen) reduces gastric

damage and improves analgesic and antiinflammatory effects in rodents. *Anesthesia and Analgesia*, *97*(2), 402–8, table of contents.

Bordji, K., Becerril-Ortega, J., & Buisson, A. (2011). Synapses, NMDA receptor activity and neuronal Aβ production in Alzheimer's disease. *Reviews in the Neurosciences*, *22*(3), 285–294.

Brecht, W. J., Harris, F. M., Chang, S., Tesseur, I., Yu, G.-Q., Xu, Q., … Huang, Y. (2004). Neuron-specific apolipoprotein e4 proteolysis is associated with increased tau phosphorylation in brains of transgenic mice. *The Journal of Neuroscience : The Official Journal of the Society for Neuroscience*, *24*(10), 2527–34.

Brinton, R. D., Yao, J., Yin, F., Mack, W. J., & Cadenas, E. (2015). Perimenopause as a neurological transition state. *Nature Reviews. Endocrinology*, *11*(7), 393–405.

Brookmeyer, R., Johnson, E., Ziegler-Graham, K., & Arrighi, H. M. (2007). Forecasting the global burden of Alzheimer's disease. *Alzheimer's & Dementia: The Journal of the Alzheimer's Association*, *3*(3), 186–91.

Bruce‐Keller, A. J., Umberger, G., McFall, R., & Mattson, M. P. (1999). Food restriction reduces brain damage and improves behavioral outcome following excitotoxic and metabolic insults. *Annals of Neurology*, *45*(1), 8–15.

Bu, G. (2009). Apolipoprotein E and its receptors in Alzheimer's disease: pathways, pathogenesis and therapy. *Nature Reviews. Neuroscience*, *10*(5), 333–344.

Bullock, R., Touchon, J., Bergman, H., Gambina, G., He, Y., Rapatz, G., … Lane, R. (2005). Rivastigmine and donepezil treatment in moderate to

moderately-severe Alzheimer's disease over a 2-year period. *Current Medical Research and Opinion*, *21*(8), 1317–27.

Butterfield, D. A., & Pocernich, C. B. (2003). The glutamatergic system and Alzheimer's disease: therapeutic implications. *CNS Drugs*, *17*(9), 641–652.

C

Calsolaro, V., & Edison, P. (2016). Alterations in Glucose Metabolism in Alzheimer's Disease. *Recent Patents on Endocrine, Metabolic & Immune Drug Discovery*, *10*(1), 31–39.

Camacho, A., Huang, J. K., Delint-Ramirez, I., Yew Tan, C., Fuller, M., Lelliott, C. J., … Franklin, R. J. M. (2013). Peroxisome proliferator-activated receptor gamma-coactivator-1 alpha coordinates sphingolipid metabolism, lipid raft composition and myelin protein synthesis. *The European Journal of Neuroscience*, *38*(5), 2672–83.

Campos-Peña, V. & Meraz-Ríos, M.A. (2014). Alzheimer Disease: The Role of Aβ in the Glutamatergic System (Figura). *Neurochemistry, chapter 10*. Recuperado de https://www.intechopen.com/books/neurochemistry/alzheimer-disease-the-role-of-a-in-the-glutamatergic-system

Cao, D., Lu, H., Lewis, T. L., & Li, L. (2007). Intake of sucrose-sweetened water induces insulin resistance and exacerbates memory deficits and amyloidosis in a transgenic mouse model of Alzheimer disease. *The Journal of Biological Chemistry*, *282*(50), 36275–82.

Cárdenas-Aguayo, M. del C., Cortes-Ortiz, M., Jiménes-Ramos, B., Gómez-Virgilio, L., Ramírez-Rodríguez, G., Vera-Arroyo, E., ... Meraz-Ríos, M.A.

(2014) Physiological Role of Amyloid Beta in Neural Cells: The Cellular Trophic Activity. (Figura). *Neurochemist*ry, *chapter 9*. Recuperado de https://www.intechopen.com/books/neurochemistry/physiological-role-of-amyloid-beta-in-neural-cells-the-cellular-trophic-activity

Carroll, J. C., Rosario, E. R., Chang, L., Stanczyk, F. Z., Oddo, S., LaFerla, F. M., & Pike, C. J. (2007). Progesterone and Estrogen Regulate Alzheimer-Like Neuropathology in Female 3xTg-AD Mice. *Journal of Neuroscience*, *27*(48), 13357–13365.

Carson, J. A., & Turner, A. J. (2002). Beta-amyloid catabolism: roles for neprilysin (NEP) and other metallopeptidases? *Journal of Neurochemistry*, *81*(1), 1–8.

Carter, C. L., Resnick, E. M., Mallampalli, M., & Kalbarczyk, A. (2012). Sex and gender differences in Alzheimer's disease: recommendations for future research. *Journal of Women's Health (2002)*, *21*(10), 1018–23.

Carvalho, C., Cardoso, S., Correia, S. C., Santos, R. X., Santos, M. S., Baldeiras, I., … Moreira, P. I. (2012). Metabolic alterations induced by sucrose intake and Alzheimer's disease promote similar brain mitochondrial abnormalities. *Diabetes*, *61*(5), 1234–42.

Caspersen, C., Wang, N., Yao, J., Sosunov, A., Chen, X., Lustbader, J. W., … Yan, S. Du. (2005). Mitochondrial A : a potential focal point for neuronal metabolic dysfunction in Alzheimer's disease. *The FASEB Journal*, *19*(14), 2040–1.

Chang, S., ran Ma, T., Miranda, R. D., Balestra, M. E., Mahley, R. W., & Huang, Y. (2005). Lipid- and receptor-binding regions of apolipoprotein E4 fragments act in concert to cause mitochondrial dysfunction and neurotoxicity.

Proceedings of the National Academy of Sciences of the United States of America, *102*(51), 18694–9.

Cheng, A., Wan, R., Yang, J.-L., Kamimura, N., Son, T. G., Ouyang, X., … Mattson, M. P. (2012). Involvement of PGC-1α in the formation and maintenance of neuronal dendritic spines. *Nature Communications*, *3*, 1250.

Chua, L.-M., Lim, M.-L., Chong, P.-R., Hu, Z. P., Cheung, N. S., & Wong, B.-S. (2012). Impaired neuronal insulin signaling precedes Aβ42 accumulation in female AβPPsw/PS1ΔE9 mice. *Journal of Alzheimer's Disease: JAD*, *29*(4), 783–91.

Clarke, J. R., Lyra E Silva, N. M., Figueiredo, C. P., Frozza, R. L., Ledo, J. H., Beckman, D., … De Felice, F. G. (2015). Alzheimer-associated Aβ oligomers impact the central nervous system to induce peripheral metabolic deregulation. *EMBO Molecular Medicine*, *7*(2), 190–210.

Claxton, A., Baker, L. D., Hanson, A., Trittschuh, E. H., Cholerton, B., Morgan, A., … Craft, S. (2015). Long-acting intranasal insulin detemir improves cognition for adults with mild cognitive impairment or early-stage Alzheimer's disease dementia. *Journal of Alzheimer's Disease : JAD*, *44*(3), 897–906.

Claxton, A., Baker, L. D., Wilkinson, C. W., Trittschuh, E. H., Chapman, D., Watson, G. S., … Craft, S. (2013). Sex and ApoE genotype differences in treatment response to two doses of intranasal insulin in adults with mild cognitive impairment or Alzheimer's disease. *Journal of Alzheimer's Disease : JAD*, *35*(4), 789–97.

Corder, E. H., Saunders, A. M., Strittmatter, W. J., Schmechel, D. E., Gaskell, P. C., Small, G. W., … Pericak-Vance, M. A. (1993). Gene dose of

apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. *Science (New York, N.Y.)*, *261*(5123), 921–3.

Corder, E. H., Woodbury, M. A., Volkmann, I., Madsen, D. K., Bogdanovic, N., & Winblad, B. (2000). Density profiles of Alzheimer disease regional brain pathology for the huddinge brain bank: pattern recognition emulates and expands upon Braak staging. *Experimental Gerontology*, *35*(6–7), 851–64.

Côté, S., Carmichael, P.-H., Verreault, R., Lindsay, J., Lefebvre, J., & Laurin, D. (2012). Nonsteroidal anti-inflammatory drug use and the risk of cognitive impairment and Alzheimer's disease. *Alzheimer's & Dementia: The Journal of the Alzheimer's Association*, *8*(3), 219–26.

Coyle, J. T., & Puttfarcken, P. (1993). Oxidative stress, glutamate, and neurodegenerative disorders. *Science (New York, N.Y.)*, *262*(5134), 689–95.

Crane, P. K., Walker, R., Hubbard, R. A., Li, G., Nathan, D. M., Zheng, H., … Larson, E. B. (2013). Glucose Levels and Risk of Dementia. *New England Journal of Medicine*, *369*(6), 540–548.

Cummings, J., Lee, G., Mortsdorf, T., Ritter, A., & Zhong, K. (2017). Alzheimer's disease drug development pipeline: 2017. *Alzheimer's & Dementia (New York, N. Y.)*, *3*(3), 367–384.

Czeh, M., Gressens, P., & Kaindl, A. M. (2011). The yin and yang of microglia. *Developmental Neuroscience*, *33*(3-4), 199–209.

D

Daneman, D. (2006). Type 1 diabetes. *The Lancet*, *367*(9513), 847–858.

Deane, R., Sagare, A., & Zlokovic, B. V. (2008). The role of the cell surface LRP and soluble LRP in blood-brain barrier Abeta clearance in Alzheimer's disease. *Current Pharmaceutical Design*, *14*(16), 1601–5.

Deakin, J. F. (1983). Alzheimer's disease: recent advances and future prospects. *British Medical Journal (Clinical Research Ed.)*, *287*(6402), 1323–4.

De Felice, F. G., Lourenco, M. V, & Ferreira, S. T. (2014). How does brain insulin resistance develop in Alzheimer's disease? *Alzheimer's & Dementia : The Journal of the Alzheimer's Association*, *10*(1 Suppl), S26-32.

Delacourte, A., & Defossez, A. (1986). Alzheimer's disease: Tau proteins, the promoting factors of microtubule assembly, are major components of paired helical filaments. *Journal of the Neurological Sciences*, *76*(2–3), 173–86.

De la Monte, S. M., & Wands, J. R. (2005). Review of insulin and insulin-like growth factor expression, signaling, and malfunction in the central nervous system: relevance to Alzheimer's disease. *Journal of Alzheimer's Disease : JAD*, *7*(1), 45–61.

De la Monte, S. M. (2009). Insulin resistance and Alzheimer's disease. *BMB Reports*, *42*(8), 475–81.

Di Cairano, E. S., Davalli, A. M., Perego, L., Sala, S., Sacchi, V. F., La Rosa, S., … Perego, C. (2011). The glial glutamate transporter 1 (GLT1) is expressed by pancreatic beta-cells and prevents glutamate-induced beta-cell death. *The Journal of Biological Chemistry*, *286*(16), 14007–18.

Dineley, K. T., Jahrling, J. B., & Denner, L. (2014). Insulin resistance in Alzheimer's disease. *Neurobiology of Disease*, *72 Pt A*, 92–103.

Dou, J.-T., Chen, M., Dufour, F., Alkon, D. L., & Zhao, W.-Q. (2005). Insulin receptor signaling in long-term memory consolidation following spatial learning. *Learning & Memory (Cold Spring Harbor, N.Y.)*, *12*(6), 646–55.

Du, H., Guo, L., Zhang, W., Rydzewska, M., & Yan, S. (2011). Cyclophilin D deficiency improves mitochondrial function and learning/memory in aging Alzheimer disease mouse model. *Neurobiology of Aging*, *32*(3), 398–406.

E

Eckert, A., Schmitt, K., & Götz, J. (2011). Mitochondrial dysfunction - the beginning of the end in Alzheimer's disease? Separate and synergistic modes of tau and amyloid- toxicity. *Alzheimer's Research & Therapy*, *3*(2), 15.

Edison, P., Archer, H. A., Hinz, R., Hammers, A., Pavese, N., Tai, Y. F., … Brooks, D. J. (2007). Amyloid, hypometabolism, and cognition in Alzheimer disease: an [11C]PIB and [18F]FDG PET study. *Neurology*, *68*(7), 501–8.

Eisele, Y. S., Obermüller, U., Heilbronner, G., Baumann, F., Kaeser, S. A., Wolburg, H., … Jucker, M. (2010). Peripherally applied Abeta-containing inoculates induce cerebral beta-amyloidosis. *Science (New York, N.Y.)*, *330*(6006), 980–2.

Erickson, M. A., & Banks, W. A. (2013). Blood-brain barrier dysfunction as a cause and consequence of Alzheimer's disease. *Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism*, *33*(10), 1500–13.

Ettcheto, M., Petrov, D., Pedrós, I., de Lemos, L., Pallàs, M., Alegret, M., … Camins, A. (2015). Hypercholesterolemia and neurodegeneration.

Comparison of hippocampal phenotypes in LDLr knockout and APPswe/PS1dE9 mice. *Experimental Gerontology*, *65*, 69–78.

F

Farina, C., Aloisi, F., & Meinl, E. (2007). Astrocytes are active players in cerebral innate immunity. *Trends in Immunology*, *28*(3), 138–145.

Farrer, L. A., Cupples, L. A., Haines, J. L., Hyman, B., Kukull, W. A., Mayeux, R., … van Duijn, C. M. (1997). Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium. *JAMA*, *278*(16), 1349–56.

Fernández Martínez, M., Castro Flores, J., Pérez de las Heras, S., Mandaluniz Lekumberri, A., Gordejuela Menocal, M., & Zarranz Imirizaldu, J. J. (2008). Risk factors for dementia in the epidemiological study of Munguialde County (Basque Country-Spain). *BMC Neurology*, *8*(1), 39.

Ferreira, S. T., Clarke, J. R., Bomfim, T. R., & De Felice, F. G. (2014). Inflammation, defective insulin signaling, and neuronal dysfunction in Alzheimer's disease. *Alzheimer's & Dementia*, *10*(1), S76–S83.

Ferreira, S. T., Vieira, M. N. N., & De Felice, F. G. (2007). Soluble protein oligomers as emerging toxins in Alzheimer's and other amyloid diseases. *IUBMB Life*, *59*(4–5), 332–45.

Folch, J., Busquets, O., Ettcheto, M., Sánchez-López, E., Castro-Torres, R. D., Verdaguer, E., … Camins, A. (2017). Memantine for the Treatment of

Dementia: A Review on its Current and Future Applications. *Journal of Alzheimer's Disease*, 1–18.

Friedland, R. P. (2003). Fish consumption and the risk of Alzheimer disease: is it time to make dietary recommendations? *Archives of Neurology*, *60*(7), 923–4.

Fröjdö, S., Vidal, H., & Pirola, L. (2009). Alterations of insulin signaling in type 2 diabetes: a review of the current evidence from humans. *Biochimica et Biophysica Acta*, *1792*(2), 83–92.

Fuentes, F., Zimmer, D., Atienza, M., Schottenfeld, J., Penkala, I., Bale, T., … Arregui, C. O. (2012). Protein tyrosine phosphatase PTP1B is involved in hippocampal synapse formation and learning. *PloS One*, *7*(7), e41536.

G

Gamba, P., Testa, G., Sottero, B., Gargiulo, S., Poli, G., & Leonarduzzi, G. (2012). The link between altered cholesterol metabolism and Alzheimer's disease. *Annals of the New York Academy of Sciences*, *1259*(1), 54–64.

Garcia-Alloza, M., Robbins, E. M., Zhang-Nunes, S. X., Purcell, S. M., Betensky, R. A., Raju, S., … Frosch, M. P. (2006). Characterization of amyloid deposition in the APPswe/PS1dE9 mouse model of Alzheimer disease. *Neurobiology of Disease*, *24*(3), 516–524.

Gerzon, K., Krumkalns, E. V, Brindle, R. L., Marshall, F. J., & Root, M. A. (1963). The adamantyl group in medicinal agents. I. Hypoglycemic N-arylsulfonyl-N´-adamantylureas. *Journal of Medicinal Chemistry*, *6*, 760–3.

Gibson, G. E., Sheu, K. F., Blass, J. P., Baker, A., Carlson, K. C., Harding, B., & Perrino, P. (1988). Reduced activities of thiamine-dependent enzymes in the brains and peripheral tissues of patients with Alzheimer's disease. *Archives of Neurology*, *45*(8), 836–40.

Gispen, W. H., & Biessels, G. J. (2000). Cognition and synaptic plasticity in diabetes mellitus. *Trends in Neurosciences*, *23*(11), 542–549.

Glass, C. K., Saijo, K., Winner, B., Marchetto, M. C., & Gage, F. H. (2010). Mechanisms Underlying Inflammation in Neurodegeneration. *Cell*, *140*(6), 918–934.

Glenner, G. G., & Wong, C. W. (1984). Alzheimer's disease and Down's syndrome: Sharing of a unique cerebrovascular amyloid fibril protein. *Biochemical and Biophysical Research Communications*, *122*(3), 1131–1135.

Gold, S. M., Dziobek, I., Sweat, V., Tirsi, A., Rogers, K., Bruehl, H., … Convit, A. (2007). Hippocampal damage and memory impairments as possible early brain complications of type 2 diabetes. *Diabetologia*, *50*(4), 711–719.

Goldstein, J. L., Basu, S. K., Brunschede, G. Y., & Brown, M. S. (1976). Release of low density lipoprotein from its cell surface receptor by sulfated glycosaminoglycans. *Cell*, *7*(1), 85–95.

Goldstein, J. L., & Brown, M. S. (1974). Binding and degradation of low density lipoproteins by cultured human fibroblasts. Comparison of cells from a normal subject and from a patient with homozygous familial hypercholesterolemia. *The Journal of Biological Chemistry*, *249*(16), 5153–62.

Gómez-Isla, T., Hollister, R., West, H., Mui, S., Growdon, J. H., Petersen, R. C., … Hyman, B. T. (1997). Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer's disease. *Annals of Neurology*, *41*(1), 17–24.

Greenamyre, J. T., & Porter, R. H. (1994). Anatomy and physiology of glutamate in the CNS. *Neurology*, *44*(11 Suppl 8), S7-13.

Guimerà, A., Gironès, X., Cruz-Sánchez, F. F. (2002). Actualización sobre la Enfermedad de Alzheimer. *Revista Española de Patología*, *35*(1), 21–48

H

Haan, M. N. (2006). Therapy Insight: type 2 diabetes mellitus and the risk of late-onset Alzheimer's disease. *Nature Clinical Practice. Neurology*, *2*(3), 159–66.

Habbas, S., Santello, M., Becker, D., Stubbe, H., Zappia, G., Liaudet, N., … Volterra, A. (2015). Neuroinflammatory TNFα Impairs Memory via Astrocyte Signaling. *Cell*, *163*(7), 1730–41.

Hall, A. M., & Roberson, E. D. (2012). Mouse models of Alzheimer's disease. *Brain Research Bulletin*, *88*(1), 3–12.

Han, W., & Li, C. (2010). Linking type 2 diabetes and Alzheimer's disease. *Proceedings of the National Academy of Sciences of the United States of America*, *107*(15), 6557–8.

Handschin, C., & Spiegelman, B. M. (2006). Peroxisome Proliferator-Activated Receptor γ Coactivator 1 Coactivators, Energy Homeostasis, and Metabolism. *Endocrine Reviews*, *27*(7), 728–735.

Hanisch, U. K., & Kettenmann, H. (2007). Microglia: active sensor and versatile effector cells in the normal and pathologic brain. *Nature Neuroscience*, *10*(11), 1387–94.

Hardy, J., & Allsop, D. (1991). Amyloid deposition as the central event in the aetiology of Alzheimer's disease. *Trends in Pharmacological Sciences*, *12*(10), 383–8.

Hardy, J. A., & Higgins, G. A. (1992). Alzheimer's disease: the amyloid cascade hypothesis. *Science (New York, N.Y.)*, *256*(5054), 184–5.

Hardy, J., & Selkoe, D. J. (2002). The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. *Science (New York, N.Y.)*, *297*(5580), 353–6.

Havrankova, J., Roth, J., & Brownstein, M. J. (1979). Concentrations of insulin and insulin receptors in the brain are independent of peripheral insulin levels. Studies of obese and streptozotocin-treated rodents. *The Journal of Clinical Investigation*, *64*(2), 636–42.

Hensley, K. (2010). Neuroinflammation in Alzheimer's disease: mechanisms, pathologic consequences, and potential for therapeutic manipulation. *Journal of Alzheimer's Disease: 21*(1), 1–14

Hernández, F., Gómez de Barreda, E., Fuster-Matanzo, A., Lucas, J. J., & Avila, J. (2010). GSK3: a possible link between beta amyloid peptide and tau protein. *Experimental Neurology*, *223*(2), 322–5.

Hickman, S. E., Allison, E. K., & El Khoury, J. (2008). Microglial dysfunction and defective beta-amyloid clearance pathways in aging Alzheimer's disease mice. *The Journal of Neuroscience: The Official Journal of the Society for Neuroscience*, *28*(33), 8354–60.

Ho, L., Qin, W., Pompl, P. N., Xiang, Z., Wang, J., Zhao, Z., … Pasinetti, G. M. (2004). Diet-induced insulin resistance promotes amyloidosis in a transgenic mouse model of Alzheimer's disease. *The FASEB Journal*, *18*(7), 902–904.

Hokama, M., Oka, S., Leon, J., Ninomiya, T., Honda, H., Sasaki, K., … Nakabeppu, Y. (2014). Altered Expression of Diabetes-Related Genes in Alzheimer's Disease Brains: The Hisayama Study. *Cerebral Cortex*, *24*(9), 2476–2488.

Holtzman, D. M., Morris, J. C. and Goate, A. M. (2011) 'Alzheimer's disease: the challenge of the second century.', *Science translational medicine*, 3(77), p. 77sr1.

Hooper, C., Killick, R., & Lovestone, S. (2008). The GSK3 hypothesis of Alzheimer's disease. *Journal of Neurochemistry*, *104*(6), 1433–9.

Hoozemans, J. J. M., Veerhuis, R., Rozemuller, J. M., & Eikelenboom, P. (2006). Neuroinflammation and regeneration in the early stages of Alzheimer's disease pathology. *International Journal of Developmental Neuroscience: The Official Journal of the International Society for Developmental Neuroscience*, *24*(2–3), 157–165.

I

in t' Veld, B. A., Ruitenberg, A., Hofman, A., Launer, L. J., van Duijn, C. M., Stijnen, T., … Stricker, B. H. (2001). Nonsteroidal antiinflammatory drugs and the risk of Alzheimer's disease. *The New England Journal of Medicine*, *345*(21), 1515–21

Inglis, F. (2002). The tolerability and safety of cholinesterase inhibitors in the treatment of dementia. *International Journal of Clinical Practice. Supplement*, (127), 45–63.

Innerarity, T. L., Pitas, R. E., & Mahley, R. W. (1986). Lipoprotein-receptor interactions. *Methods in Enzymology*, *129*, 542–565.

Irvine, K., Laws, K. R., Gale, T. M., & Kondel, T. K. (2012). Greater cognitive deterioration in women than men with Alzheimer's disease: a meta analysis. *Journal of Clinical and Experimental Neuropsychology*, *34*(9), 989–98.

Ito, K., Tatebe, T., Suzuki, K., Hirayama, T., Hayakawa, M., Kubo, H., … Makino, M. (2017). Memantine reduces the production of amyloid-β peptides through modulation of amyloid precursor protein trafficking. *European Journal of Pharmacology*, *798*, 16–25.

J

Jankowsky, J. L., Fadale, D. J., Anderson, J., Xu, G. M., Gonzales, V., Jenkins, N. A., … Borchelt, D. R. (2004). Mutant presenilins specifically elevate the levels of the 42 residue beta-amyloid peptide in vivo: evidence for

augmentation of a 42-specific gamma secretase. *Human Molecular Genetics*, *13*(2), 159–70.

Jarrett, J. T., Berger, E. P., & Lansbury, P. T. (1993). The C-terminus of the beta protein is critical in amyloidogenesis. *Annals of the New York Academy of Sciences*, *695*, 144–8.

Jellinger, K. A. (2004). Head injury and dementia. *Current Opinion in Neurology*, *17*(6), 719–23.

Jha, N. K., Jha, S. K., Kumar, D., Kejriwal, N., Sharma, R., Ambasta, R. K., & Kumar, P. (2015). Impact of Insulin Degrading Enzyme and Neprilysin in Alzheimer's Disease Biology: Characterization of Putative Cognates for Therapeutic Applications. *Journal of Alzheimer's Disease: JAD*, *48*(4), 891–917.

Jin, M., Shepardson, N., Yang, T., Chen, G., Walsh, D., & Selkoe, D. J. (2011). Soluble amyloid beta-protein dimers isolated from Alzheimer cortex directly induce Tau hyperphosphorylation and neuritic degeneration. *Proceedings of the National Academy of Sciences of the United States of America*, *108*(14), 5819–24.

Jing, Z., Caltagarone, J., & Bowser, R. (2009). Altered subcellular distribution of c-Abl in Alzheimer's disease. *Journal of Alzheimer's Disease: JAD*, *17*(2), 409–22.

Joachim, C. L., Mori, H., & Selkoe, D. J. (1989). Amyloid β-protein deposition in tissues other than brain in Alzheimer's disease. *Nature*, *341*(6239), 226–230.

Jope, R. S., Yuskaitis, C. J., & Beurel, E. (2007). Glycogen synthase kinase-3 (GSK3): inflammation, diseases, and therapeutics. *Neurochemical Research*, *32*(4–5), 577–95.

Julien, C., Tremblay, C., Phivilay, A., Berthiaume, L., Emond, V., Julien, P., & Calon, F. (2010). High-fat diet aggravates amyloid-beta and tau pathologies in the 3xTg-AD mouse model. *Neurobiology of Aging*, *31*(9), 1516–31.

K

Kaehler, S. T., Phleps, W., & Hesse, E. (2003). Dexibuprofen: pharmacology, therapeutic uses and safety. *Inflammopharmacology*, *11*(4), 371–83.

Kalmijn, S., Launer, L. J., Ott, A., Witteman, J. C., Hofman, A., & Breteler, M. M. (1997). Dietary fat intake and the risk of incident dementia in the Rotterdam Study. *Annals of Neurology*, *42*(5), 776–82.

Kandel, E. R. (2012). The molecular biology of memory: cAMP, PKA, CRE, CREB-1, CREB-2, and CPEB. *Molecular Brain*, *5*(1), 14.

Katsouri, L., Parr, C., Bogdanovic, N., Willem, M., & Sastre, M. (2011). PPARγ co-activator-1α (PGC-1α) reduces amyloid-β generation through a PPARγ-dependent mechanism. *Journal of Alzheimer's Disease: JAD*, *25*(1), 151–62.

Kew, J. N. C., & Kemp, J. A. (2005). Ionotropic and metabotropic glutamate receptor structure and pharmacology. *Psychopharmacology*, *179*(1), 4–29.

Khachaturian, Z. S. (1985). Diagnosis of Alzheimer's disease. *Archives of Neurology*, *42*(11), 1097–105.

Kim, T.-S., Pae, C.-U., Yoon, S.-J., Jang, W.-Y., Lee, N. J., Kim, J.-J., … Lee, C.-U. (2006). Decreased plasma antioxidants in patients with Alzheimer's disease. *International Journal of Geriatric Psychiatry*, *21*(4), 344–348.

Kimura, T., Hatsuta, H., Masuda-Suzukake, M., Hosokawa, M., Ishiguro, K., Akiyama, H., … Hisanaga, S. (2016). The Abundance of Nonphosphorylated Tau in Mouse and Human Tauopathy Brains Revealed by the Use of Phos-Tag Method. *The American Journal of Pathology*, *186*(2), 398–409.

Kish, S. J., Bergeron, C., Rajput, A., Dozic, S., Mastrogiacomo, F., Chang, L. J., … Nobrega, J. N. (1992). Brain cytochrome oxidase in Alzheimer's disease. *Journal of Neurochemistry*, *59*(2), 776–9.

Knight, E. M., Martins, I. V. A., Gümüsgöz, S., Allan, S. M., & Lawrence, C. B. (2014). High-fat diet-induced memory impairment in triple-transgenic Alzheimer's disease (3xTgAD) mice is independent of changes in amyloid and tau pathology. *Neurobiology of Aging*, *35*(8), 1821–32.

Knutti, D., & Kralli, A. (2001). PGC-1, a versatile coactivator. *Trends in Endocrinology and Metabolism: TEM*, *12*(8), 360–5.

Kowalska, A., Pruchnik-Wolińska, D., Florczak, J., Modestowicz, R., Szczech, J., Kozubski, W., … Wender, M. (2004). Genetic study of familial cases of Alzheimer's disease. *Acta Biochimica Polonica*, *51*(1), 245–252.

Kuhn, P.-H., Wang, H., Dislich, B., Colombo, A., Zeitschel, U., Ellwart, J. W., … Lichtenthaler, S. F. (2010). ADAM10 is the physiologically relevant, constitutive alpha-secretase of the amyloid precursor protein in primary neurons. *The EMBO Journal*, *29*(17), 3020–3032.

L

Laird, F. M., Cai, H., Savonenko, A. V, Farah, M. H., He, K., Melnikova, T., … Wong, P. C. (2005). BACE1, a major determinant of selective vulnerability of the brain to amyloid-beta amyloidogenesis, is essential for cognitive, emotional, and synaptic functions. *The Journal of Neuroscience: The Official Journal of the Society for Neuroscience*, *25*(50), 11693–709.

Lawson, L. J., Perry, V. H., Dri, P., & Gordon, S. (1990). Heterogeneity in the distribution and morphology of microglia in the normal adult mouse brain. *Neuroscience*, *39*(1), 151–70.

Leboucher, A., Laurent, C., Fernandez-Gomez, F.-J., Burnouf, S., Troquier, L., Eddarkaoui, S., … Blum, D. (2013). Detrimental effects of diet-induced obesity on τ pathology are independent of insulin resistance in τ transgenic mice. *Diabetes*, *62*(5), 1681–8.

Lechin, F., van der Dijs, B., Pardey-Maldonado, B., Rivera, J. E., Lechin, M. E., & Baez, S. (2009). Amantadine reduces glucagon and enhances insulin secretion throughout the oral glucose tolerance test: central plus peripheral nervous system mechanisms. *Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy*, *2*, 203–13.

Lee, J., & Pilch, P. F. (1994). The insulin receptor: structure, function, and signaling. *The American Journal of Physiology*, *266*(2 Pt 1), C319-34.

Lee, Y.-H., Tharp, W. G., Maple, R. L., Nair, S., Permana, P. A., & Pratley, R. E. (2008). Amyloid Precursor Protein Expression Is Upregulated in Adipocytes in Obesity. *Obesity*, *16*(7), 1493

Leissring, M. A., Farris, W., Chang, A. Y., Walsh, D. M., Wu, X., Sun, X., … Selkoe, D. J. (2003). Enhanced proteolysis of beta-amyloid in APP transgenic mice prevents plaque formation, secondary pathology, and premature death. *Neuron*, *40*(6), 1087–93.

Leuner, K., Hauptmann, S., Abdel-Kader, R., Scherping, I., Keil, U., Strosznajder, J. B., … Müller, W. E. (2007). Mitochondrial dysfunction: the first domino in brain aging and Alzheimer's disease? *Antioxidants & Redox Signaling*, *9*(10), 1659–75.

Léveillé, F., El Gaamouch, F., Gouix, E., Lecocq, M., Lobner, D., Nicole, O., & Buisson, A. (2008). Neuronal viability is controlled by a functional relation between synaptic and extrasynaptic NMDA receptors. *FASEB Journal: Official Publication of the Federation of American Societies for Experimental Biology*, *22*(12), 4258–4271.

Lewczuk, P., Mroczko, B., Fagan, A., & Kornhuber, J. (2015). Biomarkers of Alzheimer's disease and mild cognitive impairment: a current perspective. *Advances in Medical Sciences*, *60*(1), 76–82.

Li, J., Zhao, W.-G., Shen, Z.-F., Yuan, T., Liu, S.-N., Liu, Q., … Sun, W. (2015). Comparative Proteome Analysis of Brown Adipose Tissue in Obese C57BL/6J Mice Using iTRAQ-Coupled 2D LC-MS/MS. *PLOS ONE*, *10*(3), e0119350.

Li, Q. X., Fuller, S. J., Beyreuther, K., & Masters, C. L. (1999). The amyloid precursor protein of Alzheimer disease in human brain and blood. *Journal of Leukocyte Biology*, *66*(4), 567–74.

Li, Y., Rinne, J. O., Mosconi, L., Pirraglia, E., Rusinek, H., DeSanti, S., … de Leon, M. J. (2008). Regional analysis of FDG and PIB-PET images in normal

aging, mild cognitive impairment, and Alzheimer's disease. *European Journal of Nuclear Medicine and Molecular Imaging*, *35*(12), 2169–81.

Li, W., Poteet, E., Xie, L., Liu, R., Wen, Y., & Yang, S.-H. (2011). Regulation of matrix metalloproteinase 2 by oligomeric amyloid β protein. *Brain Research*, *1387*, 141–8.

Lipton, S. A., Rosenberg, P. A., & Rosenberg, P. A. (1994). Excitatory amino acids as a final common pathway for neurologic disorders. *The New England Journal of Medicine*, *330*(9), 613–22.

Liu, B., & Hong, J.-S. (2003). Role of microglia in inflammation-mediated neurodegenerative diseases: mechanisms and strategies for therapeutic intervention. *The Journal of Pharmacology and Experimental Therapeutics*, *304*(1), 1–7.

Liu, C.-C., Hu, J., Tsai, C.-W., Yue, M., Melrose, H. L., Kanekiyo, T., & Bu, G. (2015). Neuronal LRP1 regulates glucose metabolism and insulin signaling in the brain. *The Journal of Neuroscience : The Official Journal of the Society for Neuroscience*, *35*(14), 5851–9.

Liu, Y., Zhang, Y.-W., Wang, X., Zhang, H., You, X., Liao, F.-F., & Xu, H. (2009). Intracellular trafficking of presenilin 1 is regulated by beta-amyloid precursor protein and phospholipase D1. *The Journal of Biological Chemistry*, *284*(18), 12145–52.

Liu, Y., Liu, F., Grundke-Iqbal, I., Iqbal, K., & Gong, C.-X. (2011). Deficient brain insulin signalling pathway in Alzheimer's disease and diabetes. *The Journal of Pathology*, *225*(1), 54–62.

Lowell, B. B., & Shulman, G. I. (2005). Mitochondrial Dysfunction and Type 2 Diabetes. *Science*, *307*(5708), 384–387.

Luchsinger, J. A., Tang, M.-X., Shea, S., & Mayeux, R. (2002). Caloric intake and the risk of Alzheimer disease. *Archives of Neurology*, *59*(8), 1258–63.

Luchsinger, J. A., Reitz, C., Honig, L. S., Tang, M. X., Shea, S., & Mayeux, R. (2005). Aggregation of vascular risk factors and risk of incident Alzheimer disease. *Neurology*, *65*(4), 545–551.

Lye, T. C., & Shores, E. A. (2000). Traumatic brain injury as a risk factor for Alzheimer's disease: a review. *Neuropsychology Review*, *10*(2), 115–129.

M

Maccioni, R. B., Muñoz, J. P., & Barbeito, L. (2001). The molecular bases of Alzheimer's disease and other neurodegenerative disorders. *Archives of Medical Research*, *32*(5), 367–81.

Mackenzie, I. R., & Munoz, D. G. (1998). Nonsteroidal anti-inflammatory drug use and Alzheimer-type pathology in aging. *Neurology*, *50*(4), 986–90.

Macklin, L., Griffith, C. M., Cai, Y., Rose, G. M., Yan, X.-X., & Patrylo, P. R. (2017). Glucose tolerance and insulin sensitivity are impaired in APP/PS1 transgenic mice prior to amyloid plaque pathogenesis and cognitive decline. *Experimental Gerontology*, *88*, 9–18.

Maesako, M., Uemura, K., Iwata, A., Kubota, M., Watanabe, K., Uemura, M., … Kinoshita, A. (2013). Continuation of exercise is necessary to inhibit high

fat diet-induced β-amyloid deposition and memory deficit in amyloid precursor protein transgenic mice. *PloS One*, *8*(9), e72796.

Mahley, R. (1988). Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. *Science*, *240*(4852), 622–630.

Marquard, J., Otter, S., Welters, A., Stirban, A., Fischer, A., Eglinger, J., … Lammert, E. (2015). Characterization of pancreatic NMDA receptors as possible drug targets for diabetes treatment. *Nature Medicine*, *21*(4), 363–72.

Marsa, L. (2015) Cracking the Alzheimer´s Code; Are we close to conquering one of the most puzzling disease of our time? *Science for the curious discover*. Recuperado de: http://discovermagazine.com/2015/march/16-cracking-the-alzheimers-code

Masliah, E., Mallory, M., Alford, M., DeTeresa, R., Hansen, L. A., McKeel, D. W., & Morris, J. C. (2001). Altered expression of synaptic proteins occurs early during progression of Alzheimer's disease. *Neurology*, *56*(1), 127–9.

Mao, Y.-F., Guo, Z., Zheng, T., Jiang, Y., Yan, Y., Yin, X., … Zhang, B. (2016). Intranasal insulin alleviates cognitive deficits and amyloid pathology in young adult APPswe/PS1dE9 mice. *Aging Cell*, *15*(5), 893–902.

Maragakis, N. J., & Rothstein, J. D. (2006). Mechanisms of Disease: astrocytes in neurodegenerative disease. *Nature Clinical Practice. Neurology*, *2*(12), 679–89.

Markesbery, W. R. (1997). Oxidative stress hypothesis in Alzheimer's disease. *Free Radical Biology & Medicine*, *23*(1), 134–47.

Markesbery, W. R., & Carney, J. M. (1999). Oxidative alterations in Alzheimer's disease. *Brain Pathology (Zurich, Switzerland)*, *9*(1), 133–46.

Margolis, R. U., & Altszuler, N. (1967). Insulin in the cerebrospinal fluid. *Nature*, *215*(5108), 1375–6.

Martinez, A., Castro, A., Dorronsoro, I., & Alonso, M. (2002). Glycogen synthase kinase 3 (GSK-3) inhibitors as new promising drugs for diabetes, neurodegeneration, cancer, and inflammation. *Medicinal Research Reviews*, *22*(4), 373–84.

Masters, C. L., & Beyreuther, K. (2006). Alzheimer's centennial legacy: prospects for rational therapeutic intervention targeting the Abeta amyloid pathway. *Brain: A Journal of Neurology*, *129*(Pt 11), 2823–39.

Mattson, M. P. (2000). Neuroprotective signaling and the aging brain: take away my food and let me run. *Brain Research*, *886*(1–2), 47–53.

Mattson, M. P. (2004). Pathways towards and away from Alzheimer's disease. *Nature*, *430*(7000), 631–639.

Mawuenyega, K. G., Sigurdson, W., Ovod, V., Munsell, L., Kasten, T., Morris, J. C., … Bateman, R. J. (2010). Decreased Clearance of CNS -Amyloid in Alzheimer's Disease. *Science*, *330*(6012), 1774–1774.

Maynard, C. J. *et al.* (2006) 'Gender and genetic background effects on brain metal levels in APP transgenic and normal mice: implications for Alzheimer beta-amyloid pathology.', *Journal of inorganic biochemistry*, 100(5–6), pp. 952–62

McCrimmon, R. J., Ryan, C. M., & Frier, B. M. (2012). Diabetes and cognitive dysfunction. *Lancet (London, England)*, *379*(9833), 2291–9.

McGeer, E. G., & McGeer, P. L. (2010). Neuroinflammation in Alzheimer's disease and mild cognitive impairment: a field in its infancy. *Journal of Alzheimer's Disease : JAD*, *19*(1), 355–61

McGeer, P. L., Schulzer, M., & McGeer, E. G. (1996). Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease: a review of 17 epidemiologic studies. *Neurology*, *47*(2), 425–32.

Mejía-Arango, S., & Zúñiga-Gil, C. (2011). [Diabetes mellitus as a risk factor for dementia in the Mexican elder population]. *Revista de Neurologia*, *53*(7), 397–405.

Mesulam, M. (2004). The cholinergic lesion of Alzheimer's disease: pivotal factor or side show? *Learning & Memory (Cold Spring Harbor, N.Y.)*, *11*(1), 43–9.

Miners, J. S., Van Helmond, Z., Chalmers, K., Wilcock, G., Love, S., & Kehoe, P. G. (2006). Decreased expression and activity of neprilysin in Alzheimer disease are associated with cerebral amyloid angiopathy. *Journal of Neuropathology and Experimental Neurology*, *65*(10), 1012–21.

Mohs, R. C., Doody, R. S., Morris, J. C., Ieni, J. R., Rogers, S. L., Perdomo, C. A., … "312" Study Group. (2001). A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients. *Neurology*, *57*(3), 481–8.

Molteni, R., Barnard, R. J., Ying, Z., Roberts, C. K., & Gómez-Pinilla, F. (2002). A high-fat, refined sugar diet reduces hippocampal brain-derived

neurotrophic factor, neuronal plasticity, and learning. *Neuroscience*, *112*(4), 803–14.

Moreira, E. L. G., de Oliveira, J., Nunes, J. C., Santos, D. B., Nunes, F. C., Vieira, D. S. C., … Prediger, R. D. (2012). Age-related cognitive decline in hypercholesterolemic LDL receptor knockout mice (LDLr-/-): evidence of antioxidant imbalance and increased acetylcholinesterase activity in the prefrontal cortex. *Journal of Alzheimer's Disease: JAD*, *32*(2), 495–511.

Moreira, P. I., Santos, M. S., & Oliveira, C. R. (2007). Alzheimer's disease: a lesson from mitochondrial dysfunction. *Antioxidants & Redox Signaling*, *9*(10), 1621–30.

Morgen, K., & Frölich, L. (2015). The metabolism hypothesis of Alzheimer's disease: from the concept of central insulin resistance and associated consequences to insulin therapy. *Journal of Neural Transmission (Vienna, Austria: 1996)*, *122*(4), 499–504.

Mori, T., Koyama, N., Segawa, T., Maeda, M., Maruyama, N., Kinoshita, N., … Town, T. (2014). Methylene blue modulates β-secretase, reverses cerebral amyloidosis, and improves cognition in transgenic mice. *The Journal of Biological Chemistry*, *289*(44), 30303–17.

Morris, G. P., Clark, I. A. and Vissel, B. (2014) 'Inconsistencies and controversies surrounding the amyloid hypothesis of Alzheimer's disease.', *Acta neuropathologica communications*, 2(1), p. 135.

Morris, M. C., Evans, D. A., Bienias, J. L., Tangney, C. C., Bennett, D. A., Aggarwal, N., … Wilson, R. S. (2003). Dietary fats and the risk of incident Alzheimer disease. *Archives of Neurology*, *60*(2), 194–200.

Morris, J. K., Honea, R. A., Vidoni, E. D., Swerdlow, R. H., & Burns, J. M. (2014). Is Alzheimer's disease a systemic disease? *Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease*, *1842*(9), 1340–1349.

N

Nazareth, A. M. de. (2017). Type 2 diabetes mellitus in the pathophysiology of Alzheimer's disease. *Dementia & Neuropsychologia*, *11*(2), 105–113.

Ni, R., Marutle, A., & Nordberg, A. (2013). Modulation of α7 nicotinic acetylcholine receptor and fibrillar amyloid-β interactions in Alzheimer's disease brain. *Journal of Alzheimer's Disease : JAD*, *33*(3), 841–51.

Nitsch, R. M., Slack, B. E., Wurtman, R. J., & Growdon, J. H. (1992). Release of Alzheimer amyloid precursor derivatives stimulated by activation of muscarinic acetylcholine receptors. *Science (New York, N.Y.)*, *258*(5080), 304–307.

Nunomura, A., Perry, G., Aliev, G., Hirai, K., Takeda, A., Balraj, E. K., … Smith, M. A. (2001). Oxidative damage is the earliest event in Alzheimer disease. *Journal of Neuropathology and Experimental Neurology*, *60*(8), 759–67.

Nuzzo, D., Picone, P., Baldassano, S., Caruana, L., Messina, E., Marino Gammazza, A., … Di Carlo, M. (2015). Insulin Resistance as Common Molecular Denominator Linking Obesity to Alzheimer's Disease. *Current Alzheimer Research*, *12*(8), 723–35.

O

Obici, S., Zhang, B. B., Karkanias, G., & Rossetti, L. (2002). Hypothalamic insulin signaling is required for inhibition of glucose production. *Nature Medicine*, *8*(12), 1376–1382.

Oksman, M., Iivonen, H., Hogyes, E., Amtul, Z., Penke, B., Leenders, I., … Tanila, H. (2006). Impact of different saturated fatty acid, polyunsaturated fatty acid and cholesterol containing diets on beta-amyloid accumulation in APP/PS1 transgenic mice. *Neurobiology of Disease*, *23*(3), 563–72.

Olin, J., & Schneider, L. (2002). Galantamine for Alzheimer's disease. *The Cochrane Database of Systematic Reviews*, (3), CD001747.

Olney, J. W., Wozniak, D. F., & Farber, N. B. (1997). Excitotoxic neurodegeneration in Alzheimer disease. New hypothesis and new therapeutic strategies. *Archives of Neurology*, *54*(10), 1234–40.

OMS (Organización Mundial de la Salud) (2017). Demencia. Recuperado febrero, 4, 2018 de http://www.who.int/mediacentre/factsheets/fs362/es/

OMS (Organización Mundial de la Salud)(2017). Diabetes. Recuperado febrero 4, 2018 de http://www.who.int/mediacentre/factsheets/fs312/es/

P

Pan, M.-H., Lai, C.-S., & Ho, C.-T. (2010). Anti-inflammatory activity of natural dietary flavonoids. *Food & Function*, *1*(1), 15–31.

Paoletti, P., Bellone, C., & Zhou, Q. (2013). NMDA receptor subunit diversity: impact on receptor properties, synaptic plasticity and disease. *Nature Reviews. Neuroscience*, *14*(6), 383–400.

Paradies, G., Petrosillo, G., Paradies, V., & Ruggiero, F. M. (2011). Mitochondrial dysfunction in brain aging: Role of oxidative stress and cardiolipin. *Neurochemistry International*, *58*(4), 447–457.

Pasinetti, G. M., Zhao, Z., Qin, W., Ho, L., Shrishailam, Y., Macgrogan, D., … Wang, J. (2007). Caloric intake and Alzheimer's disease. Experimental approaches and therapeutic implications. *Interdisciplinary Topics in Gerontology*, *35*, 159–75.

Patzke, H., Maddineni, U., Ayala, R., Morabito, M., Volker, J., Dikkes, P., … Tsai, L.-H. (2003). Partial rescue of the p35-/- brain phenotype by low expression of a neuronal-specific enolase p25 transgene. *The Journal of Neuroscience: The Official Journal of the Society for Neuroscience*, *23*(7), 2769–78.

Pedrós, I., Petrov, D., Allgaier, M., Sureda, F., Barroso, E., Beas-Zarate, C., … Camins, A. (2014). Early alterations in energy metabolism in the hippocampus of APPswe/PS1dE9 mouse model of Alzheimer's disease. *Biochimica et Biophysica Acta*, *1842*(9), 1556–66.

Peila, R., Rodriguez, B. L., & Launer, L. J. (2002). Type 2 diabetes, APOE gene, and the risk for dementia and related pathologies: The Honolulu-Asia Aging Study. *Diabetes*, *51*(4), 1256–62.

Perry, G., Nunomura, A., Hirai, K., Zhu, X., Pérez, M., Avila, J., … Smith, M. A. (2002). Is oxidative damage the fundamental pathogenic mechanism of

Alzheimer's and other neurodegenerative diseases? *Free Radical Biology & Medicine*, *33*(11), 1475–9.

Piaceri, I., Nacmias, B. and Sorbi, S. (2013) 'Genetics of familial and sporadic Alzheimer's disease.', *Frontiers in bioscience (Elite edition)*, 5, pp. 167–77.

Pimplikar, S. W., Nixon, R. A., Robakis, N. K., Shen, J., & Tsai, L.-H. (2010). Amyloid-Independent Mechanisms in Alzheimer's Disease Pathogenesis. *Journal of Neuroscience*, *30*(45), 14946–14954.

Pittel, Z., Heldman, E., Barg, J., Haring, R., & Fisher, A. (1996). Muscarinic control of amyloid precursor protein secretion in rat cerebral cortex and cerebellum. *Brain Research*, *742*(1–2), 299–304.

Plum, L., Schubert, M., & Brüning, J. C. (2005). The role of insulin receptor signaling in the brain. *Trends in Endocrinology & Metabolism*, *16*(2), 59–65.

Poirier, J. (2000). Apolipoprotein E and Alzheimer's disease. A role in amyloid catabolism. *Annals of the New York Academy of Sciences*, *924*, 81–90.

Postina, R., Schroeder, A., Dewachter, I., Bohl, J., Schmitt, U., Kojro, E., … Fahrenholz, F. (2004). A disintegrin-metalloproteinase prevents amyloid plaque formation and hippocampal defects in an Alzheimer disease mouse model. *The Journal of Clinical Investigation*, *113*(10), 1456–64.

Profenno, L. A., Porsteinsson, A. P., & Faraone, S. V. (2010). Meta-analysis of Alzheimer's disease risk with obesity, diabetes, and related disorders. *Biological Psychiatry*, *67*(6), 505–12.

Puig, K. L., Floden, A. M., Adhikari, R., Golovko, M. Y., & Combs, C. K. (2012). Amyloid precursor protein and proinflammatory changes are regulated

in brain and adipose tissue in a murine model of high fat diet-induced obesity. *PloS One*, *7*(1), e30378.

Puigserver, P., & Spiegelman, B. M. (2003). Peroxisome Proliferator-Activated Receptor-γ Coactivator 1α (PGC-1α): Transcriptional Coactivator and Metabolic Regulator. *Endocrine Reviews*, *24*(1), 78–90.

Pujadas, L., Rossi, D., Andrés, R., Teixeira, C. M., Serra-Vidal, B., Parcerisas, A., … Soriano, E. (2014). Reelin delays amyloid-beta fibril formation and rescues cognitive deficits in a model of Alzheimer's disease. *Nature Communications*, *5*, 3443.

Q

Qin, W., Haroutunian, V., Katsel, P., Cardozo, C. P., Ho, L., Buxbaum, J. D., & Pasinetti, G. M. (2009). PGC-1α Expression Decreases in the Alzheimer Disease Brain as a Function of Dementia. *Archives of Neurology*, *66*(3), 352–61.

Qin, W., Zhao, W., Ho, L., Wang, J., Walsh, K., Gandy, S., & Pasinetti, G. M. (2008). Regulation of forkhead transcription factor FoxO3a contributes to calorie restriction-induced prevention of Alzheimer's disease-type amyloid neuropathology and spatial memory deterioration. *Annals of the New York Academy of Sciences*, *1147*(1), 335–47.

Qiu, W. Q., & Folstein, M. F. (2006). Insulin, insulin-degrading enzyme and amyloid-beta peptide in Alzheimer's disease: review and hypothesis. *Neurobiology of Aging*, *27*(2), 190–8.

R

Rafalski, V. A., Ho, P. P., Brett, J. O., Ucar, D., Dugas, J. C., Pollina, E. A., … Brunet, A. (2013). Expansion of oligodendrocyte progenitor cells following SIRT1 inactivation in the adult brain. *Nature Cell Biology*, *15*(6), 614–24.

Rajasekar, N., Nath, C., Hanif, K., & Shukla, R. (2016). Inhibitory Effect of Memantine on Streptozotocin-Induced Insulin Receptor Dysfunction, Neuroinflammation, Amyloidogenesis, and Neurotrophic Factor Decline in Astrocytes. *Molecular Neurobiology*, *53*(10), 6730–6744.

Ramos-Rodriguez, J. J., Ortiz-Barajas, O., Gamero-Carrasco, C., de la Rosa, P. R., Infante-Garcia, C., Zopeque-Garcia, N., … Garcia-Alloza, M. (2014). Prediabetes-induced vascular alterations exacerbate central pathology in APPswe/PS1dE9 mice. *Psychoneuroendocrinology*, *48*, 123–35.

Ramos-Rodriguez, J. J., Spires-Jones, T., Pooler, A. M., Lechuga-Sancho, A. M., Bacskai, B. J., & Garcia-Alloza, M. (2017). Progressive Neuronal Pathology and Synaptic Loss Induced by Prediabetes and Type 2 Diabetes in a Mouse Model of Alzheimer's Disease. *Molecular Neurobiology*, *54*(5), 3428–3438.

Reddy, P. H., & Beal, M. F. (2008). Amyloid beta, mitochondrial dysfunction and synaptic damage: implications for cognitive decline in aging and Alzheimer's disease. *Trends in Molecular Medicine*, *14*(2), 45–53.

Reed, B., Villeneuve, S., Mack, W., DeCarli, C., Chui, H. C., & Jagust, W. (2014). Associations between serum cholesterol levels and cerebral amyloidosis. *JAMA Neurology*, *71*(2), 195–200.

Refolo, L. M., Malester, B., LaFrancois, J., Bryant-Thomas, T., Wang, R., Tint, G. S., … Pappolla, M. A. (2000). Hypercholesterolemia accelerates the Alzheimer's amyloid pathology in a transgenic mouse model. *Neurobiology of Disease*, *7*(4), 321–31.

Reger, M. A., Watson, G. S., Frey, W. H., Baker, L. D., Cholerton, B., Keeling, M. L., … Craft, S. (2006). Effects of intranasal insulin on cognition in memory-impaired older adults: Modulation by APOE genotype. *Neurobiology of Aging*, *27*(3), 451–458.

Reger, M. A., Watson, G. S., Green, P. S., Baker, L. D., Cholerton, B., Fishel, M. A., … Craft, S. (2008). Intranasal insulin administration dose-dependently modulates verbal memory and plasma amyloid-beta in memory-impaired older adults. *Journal of Alzheimer's Disease: JAD*, *13*(3), 323–31.

Reiman, E. M., Caselli, R. J., Yun, L. S., Chen, K., Bandy, D., Minoshima, S., … Osborne, D. (1996). Preclinical Evidence of Alzheimer's Disease in Persons Homozygous for the ε4 Allele for Apolipoprotein E. *New England Journal of Medicine*, *334*(12), 752–758.

Reiman, E. M., Chen, K., Alexander, G. E., Caselli, R. J., Bandy, D., Osborne, D., … Hardy, J. (2005). Correlations between apolipoprotein E epsilon4 gene dose and brain-imaging measurements of regional hypometabolism. *Proceedings of the National Academy of Sciences of the United States of America*, *102*(23), 8299–302.

Reisberg, B., Doody, R., Stöffler, A., Schmitt, F., Ferris, S., Möbius, H. J., & Memantine Study Group. (2003). Memantine in moderate-to-severe Alzheimer's disease. *The New England Journal of Medicine*, *348*(14), 1333–41.

Riedel, G., Platt, B., & Micheau, J. (2003). Glutamate receptor function in learning and memory. *Behavioural Brain Research*, *140*(1–2), 1–47.

Rigacci, S., Guidotti, V., Bucciantini, M., Nichino, D., Relini, A., Berti, A., & Stefani, M. (2011). Aβ(1-42) aggregates into non-toxic amyloid assemblies in the presence of the natural polyphenol oleuropein aglycon. *Current Alzheimer Research*, *8*(8), 841–52.

Ritchie, D. L., Adlard, P., Peden, A. H., Lowrie, S., Le Grice, M., Burns, K., … Ironside, J. W. (2017). Amyloid-β accumulation in the CNS in human growth hormone recipients in the UK. *Acta Neuropathologica*, *134*(2), 221–240.

Roberson, E. D., Scearce-Levie, K., Palop, J. J., Yan, F., Cheng, I. H., Wu, T., … Mucke, L. (2007). Reducing endogenous tau ameliorates amyloid beta-induced deficits in an Alzheimer's disease mouse model. *Science (New York, N.Y.)*, *316*(5825), 750–4.

Roberts, K. F., Elbert, D. L., Kasten, T. P., Patterson, B. W., Sigurdson, W. C., Connors, R. E., … Bateman, R. J. (2014). Amyloid-β efflux from the central nervous system into the plasma. *Annals of Neurology*, *76*(6), 837–44.

Rocchi, A., Orsucci, D., Tognoni, G., Ceravolo, R., & Siciliano, G. (2009). The role of vascular factors in late-onset sporadic Alzheimer's disease. Genetic and molecular aspects. *Current Alzheimer Research*, *6*(3), 224–237.

Rogawski, M. A., & Wenk, G. L. (2003). The neuropharmacological basis for the use of memantine in the treatment of Alzheimer's disease. *CNS Drug Reviews*, *9*(3), 275–308.

Roher, A. E., Kuo, Y. M., Kokjohn, K. M., Emmerling, M. R., & Gracon, S. (1999). Amyloid and lipids in the pathology of Alzheimer disease. *Amyloid: The International Journal of Experimental and Clinical Investigation: The Official Journal of the International Society of Amyloidosis*, *6*(2), 136–45.

Roher, A. E., Esh, C. L., Kokjohn, T. A., Castaño, E. M., Van Vickle, G. D., Kalback, W. M., … Sabbagh, M. N. (2009). Amyloid beta peptides in human plasma and tissues and their significance for Alzheimer's disease. *Alzheimer's & Dementia: The Journal of the Alzheimer's Association*, *5*(1), 18–29.

Rojo, L. E., Fernández, J. A., Maccioni, A. A., Jimenez, J. M., & Maccioni, R. B. (2008). Neuroinflammation: implications for the pathogenesis and molecular diagnosis of Alzheimer's disease. *Archives of Medical Research*, *39*(1), 1–16.

Román, G. C. (2003) 'Stroke, cognitive decline and vascular dementia: the silent epidemic of the 21st century.', *Neuroepidemiology*, 22(3), pp. 161–4.

Rossner, S., Lange-Dohna, C., Zeitschel, U., & Perez-Polo, J. R. (2005). Alzheimer's disease beta-secretase BACE1 is not a neuron-specific enzyme. *Journal of Neurochemistry*, *92*(2), 226–234.

Rowland, K. C., Irby, N. K., & Spirou, G. A. (2000). Specialized synapse-associated structures within the calyx of Held. *The Journal of Neuroscience : The Official Journal of the Society for Neuroscience*, *20*(24), 9135–44.

Ruan, L., Kang, Z., Pei, G., & Le, Y. (2009). Amyloid deposition and inflammation in APPswe/PS1dE9 mouse model of Alzheimer's disease. *Current Alzheimer Research*, *6*(6), 531–40.

Rush, T., & Buisson, A. (2014). Reciprocal disruption of neuronal signaling and Aβ production mediated by extrasynaptic NMDA receptors: a downward spiral. *Cell and Tissue Research*, *356*(2), 279–286.

Rusinek, H., Ha, J., Yau, P. L., Storey, P., Tirsi, A., Tsui, W. H., … Convit, A. (2015). Cerebral perfusion in insulin resistance and type 2 diabetes. *Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism*, *35*(1), 95–102.

S

Sagare, A. P., Bell, R. D., & Zlokovic, B. V. (2012). Neurovascular dysfunction and faulty amyloid β-peptide clearance in Alzheimer disease. *Cold Spring Harbor Perspectives in Medicine*, *2*(10), a011452–a011452.

Sánchez-López, E., Ettcheto, M., Egea, M. A., Espina, M., Calpena, A. C., Folch, J., … García, M. L. (2017). New potential strategies for Alzheimer's disease prevention: pegylated biodegradable dexibuprofen nanospheres administration to APPswe/PS1dE9. *Nanomedicine: Nanotechnology, Biology and Medicine*, *13*(3), 1171–1182.

Santacruz, K., Lewis, J., Spires, T., Paulson, J., Kotilinek, L., Ingelsson, M., … Ashe, K. H. (2005). Tau suppression in a neurodegenerative mouse model improves memory function. *Science (New York, N.Y.)*, *309*(5733), 476–81.

Schlatterer, S. D., Acker, C. M., & Davies, P. (2011). c-Abl in Neurodegenerative Disease. *Journal of Molecular Neuroscience*, *45*(3), 445–452.

Schneider, L. S., Mangialasche, F., Andreasen, N., Feldman, H., Giacobini, E., Jones, R., … Kivipelto, M. (2014). Clinical trials and late-stage drug development for Alzheimer's disease: an appraisal from 1984 to 2014. *Journal of Internal Medicine*, *275*(3), 251–283.

Schraen-Maschke, S., Sergeant, N., Dhaenens, C.-M., Bombois, S., Deramecourt, V., Caillet-Boudin, M.-L., … Buée, L. (2008). Tau as a biomarker of neurodegenerative diseases. *Biomarkers in Medicine*, *2*(4), 363–84.

Schwartz, M., Butovsky, O., Brück, W., & Hanisch, U.-K. (2006). Microglial phenotype: is the commitment reversible? *Trends in Neurosciences*, *29*(2), 68–74.

Schwartz, M. W., Figlewicz, D. P., Baskin, D. G., Woods, S. C., & Porte, D. (1992). Insulin in the brain: a hormonal regulator of energy balance. *Endocrine Reviews*, *13*(3), 387–414.

Segovia, G., Porras, A., Del Arco, A., & Mora, F. (2001). Glutamatergic neurotransmission in aging: a critical perspective. *Mechanisms of Ageing and Development*, *122*(1), 1–29.

Selkoe, D. J. (2002). Alzheimer's disease is a synaptic failure. *Science (New York, N.Y.)*, *298*(5594), 789–91.

Selkoe, D. J. (2011) 'Alzheimer's Disease', *Cold Spring Harbor Perspectives in Biology*, 3(7), pp. a004457–a004457. doi: 10.1101/cshperspect.a004457.

Selkoe, D. J., & Hardy, J. (2016). The amyloid hypothesis of Alzheimer's disease at 25 years. *EMBO Molecular Medicine*, *8*(6), 595–608.

Sergeant, N., Delacourte, A., & Buée, L. (2005). Tau protein as a differential biomarker of tauopathies. *Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease*, *1739*(2–3), 179–197.

Small, D. H. and Cappai, R. (2006) 'Alois Alzheimer and Alzheimer's disease: a centennial perspective.', *Journal of neurochemistry*, 99(3), pp. 708–10.

Smith, E., Hay, P., Campbell, L., & Trollor, J. N. (2011). A review of the association between obesity and cognitive function across the lifespan: implications for novel approaches to prevention and treatment. *Obesity Reviews*, *12*(9), 740–755.

Small, G. W., Mazziotta, J. C., Collins, M. T., Baxter, L. R., Phelps, M. E., Mandelkern, M. A., … Chang, L. (1995). Apolipoprotein E type 4 allele and cerebral glucose metabolism in relatives at risk for familial Alzheimer disease. *JAMA*, *273*(12), 942–7.

Snyder, E. M., Nong, Y., Almeida, C. G., Paul, S., Moran, T., Choi, E. Y., … Greengard, P. (2005). Regulation of NMDA receptor trafficking by amyloid-beta. *Nature Neuroscience*, *8*(8), 1051–8.

Solomon, A., Kåreholt, I., Ngandu, T., Winblad, B., Nissinen, A., Tuomilehto, J., … Kivipelto, M. (2007). Serum cholesterol changes after midlife and late-life cognition: twenty-one-year follow-up study. *Neurology*, *68*(10), 751–6.

Sommer, G., Kralisch, S., Lipfert, J., Weise, S., Krause, K., Jessnitzer, B., … Fasshauer, M. (2009). Amyloid precursor protein expression is induced by tumor necrosis factor alpha in 3T3-L1 adipocytes. *Journal of Cellular Biochemistry*, *108*(6), 1418–22.

Sorbi, S., Bird, E. D., & Blass, J. P. (1983). Decreased pyruvate dehydrogenase complex activity in Huntington and Alzheimer brain. *Annals of Neurology*, *13*(1), 72–78.

Spencer, J. P. E., Vafeiadou, K., Williams, R. J., & Vauzour, D. (2012). Neuroinflammation: Modulation by flavonoids and mechanisms of action. *Molecular Aspects of Medicine*, *33*(1), 83–97.

Steen, E., Terry, B. M., Rivera, E. J., Cannon, J. L., Neely, T. R., Tavares, R., … de la Monte, S. M. (2005). Impaired insulin and insulin-like growth factor expression and signaling mechanisms in Alzheimer's disease--is this type 3 diabetes? *Journal of Alzheimer's Disease : JAD*, *7*(1), 63–80.

Stewart, W. F., Kawas, C., Corrada, M., & Metter, E. J. (1997). Risk of Alzheimer's disease and duration of NSAID use. *Neurology*, *48*(3), 626–32.

Strachan, M. W., Deary, I. J., Ewing, F. M., & Frier, B. M. (1997). Is type II diabetes associated with an increased risk of cognitive dysfunction? A critical review of published studies. *Diabetes Care*, *20*(3), 438–445.

Streit, W. J. (2002). Microglia as neuroprotective, immunocompetent cells of the CNS. *Glia*, *40*(2), 133–9.

Strittmatter, W. J., & Roses, A. D. (1996). Apolipoprotein E and Alzheimer's Disease. *Annual Review of Neuroscience*, *19*(1), 53–77.

Strittmatter, W. J., Saunders, A. M., Schmechel, D., Pericak-Vance, M., Enghild, J., Salvesen, G. S., & Roses, A. D. (1993). Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. *Proceedings of the National Academy of Sciences of the United States of America*, *90*(5), 1977–81.

Sui, H., Zhang, L., Liu, Z., & Jin, Y. (2015). Atorvastatin prevents Aβ oligomer-induced neurotoxicity in cultured rat hippocampal neurons by inhibiting Tau cleavage. *Acta Pharmacologica Sinica*, *36*(5), 553–64.

Suzuki, M., Nelson, A. D., Eickstaedt, J. B., Wallace, K., Wright, L. S., & Svendsen, C. N. (2006). Glutamate enhances proliferation and neurogenesis in human neural progenitor cell cultures derived from the fetal cortex. *The European Journal of Neuroscience*, *24*(3), 645–653.

Swerdlow, R. H., Burns, J. M., & Khan, S. M. (2010). The Alzheimer's Disease Mitochondrial Cascade Hypothesis. *Journal of Alzheimer's Disease*, *20*(s2), S265–S279. http://doi.org/10.3233/JAD-2010-100339

Swerdlow, R. H., & Khan, S. M. (2004). A "mitochondrial cascade hypothesis" for sporadic Alzheimer's disease. *Medical Hypotheses*, *63*(1), 8–20.

Swerdlow, R. H., Burns, J. M., & Khan, S. M. (2014). The Alzheimer's disease mitochondrial cascade hypothesis: Progress and perspectives. *Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease*, *1842*(8), 1219–1231.

Szabados, T., Dul, C., Majtényi, K., Hargitai, J., Pénzes, Z., & Urbanics, R. (2004). A chronic Alzheimer's model evoked by mitochondrial poison sodium azide for pharmacological investigations. *Behavioural Brain Research*, *154*(1), 31–40. http://doi.org/10.1016/j.bbr.2004.01.016

T

Tabet, N. (2006). Acetylcholinesterase inhibitors for Alzheimer's disease: anti-inflammatories in acetylcholine clothing! *Age and Ageing*, *35*(4), 336–338.

Tabner, B. J., El-Agnaf, O. M. A., Turnbull, S., German, M. J., Paleologou, K. E., Hayashi, Y., … Allsop, D. (2005). Hydrogen Peroxide Is Generated during the Very Early Stages of Aggregation of the Amyloid Peptides Implicated in Alzheimer Disease and Familial British Dementia. *Journal of Biological Chemistry*, *280*(43), 35789–35792.

Takalo, M., Haapasalo, A., Martiskainen, H., Kurkinen, K. M. A., Koivisto, H., Miettinen, P., … Hiltunen, M. (2014). High-fat diet increases tau expression in the brain of T2DM and AD mice independently of peripheral metabolic status. *The Journal of Nutritional Biochemistry*, *25*(6), 634–41.

Takeda, S., Sato, N., Rakugi, H., & Morishita, R. (2011). Molecular mechanisms linking diabetes mellitus and Alzheimer disease: beta-amyloid peptide, insulin signaling, and neuronal function. *Molecular BioSystems*, *7*(6), 1822.

Tamaki, C., Ohtsuki, S., Iwatsubo, T., Hashimoto, T., Yamada, K., Yabuki, C., & Terasaki, T. (2006). Major involvement of low-density lipoprotein receptor-related protein 1 in the clearance of plasma free amyloid beta-peptide by the liver. *Pharmaceutical Research*, *23*(7), 1407–16.

Tang, B. L. (2009). Neuronal protein trafficking associated with Alzheimer disease: from APP and BACE1 to glutamate receptors. *Cell Adhesion & Migration*, *3*(1), 118–28.

Tanti, J.-F., & Jager, J. (2009). Cellular mechanisms of insulin resistance: role of stress-regulated serine kinases and insulin receptor substrates (IRS) serine phosphorylation. *Current Opinion in Pharmacology*, *9*(6), 753–62.

Tarasoff-Conway, J. M., Carare, R. O., Osorio, R. S., Glodzik, L., Butler, T., Fieremans, E., … de Leon, M. J. (2015). Clearance systems in the brain—implications for Alzheimer disease. *Nature Reviews Neurology*, *11*(8), 457–470.

Tcw, J., & Goate, A. M. (2017). Genetics of β-Amyloid Precursor Protein in Alzheimer's Disease. *Cold Spring Harbor Perspectives in Medicine*, *7*(6), a024539.

Teich, A. F., Nicholls, R. E., Puzzo, D., Fiorito, J., Purgatorio, R., Fa', M., & Arancio, O. (2015). Synaptic therapy in Alzheimer's disease: a CREB-centric approach. *Neurotherapeutics: The Journal of the American Society for Experimental NeuroTherapeutics*, *12*(1), 29–41.

Terry, A. V, & Buccafusco, J. J. (2003). The cholinergic hypothesis of age and Alzheimer's disease-related cognitive deficits: recent challenges and their implications for novel drug development. (Figura). *The Journal of Pharmacology and Experimental Therapeutics*, *306*(3), 821–7.

Terry, R. D. and Davies, P. (1980) 'Dementia of the Alzheimer Type', *Annual Review of Neuroscience*, 3(1), pp. 77–95.

Thinakaran, G., & Koo, E. H. (2008). Amyloid precursor protein trafficking, processing, and function. *The Journal of Biological Chemistry*, *283*(44), 29615–9.

Tomlinson, D. R., & Gardiner, N. J. (2008). Glucose neurotoxicity. *Nature Reviews Neuroscience*, *9*(1), 36–45.

Tremblay, M. A., Acker, C. M., & Davies, P. (2010). Tau phosphorylated at tyrosine 394 is found in Alzheimer's disease tangles and can be a product of the Abl-related kinase, Arg. *Journal of Alzheimer's Disease : JAD*, *19*(2), 721–33.

Trinchese, F., Liu, S., Battaglia, F., Walter, S., Mathews, P. M., & Arancio, O. (2004). Progressive age-related development of Alzheimer-like pathology in APP/PS1 mice. *Annals of Neurology*, *55*(6), 801–14.

Trojanowski, J. Q., & Lee, V. M.-Y. (2005). Rous-Whipple Award Lecture. The Alzheimer's brain: finding out what's broken tells us how to fix it (Figura). *The American Journal of Pathology*, *167*(5), 1183–1188.

Troncone, L., Luciani, M., Coggins, M., Wilker, E. H., Ho, C.-Y., Codispoti, K. E., … Del Monte, F. (2016). Aβ Amyloid Pathology Affects the Hearts of Patients With Alzheimer's Disease: Mind the Heart. *Journal of the American College of Cardiology*, *68*(22), 2395–2407.

Turner, A. J., Fisk, L., & Nalivaeva, N. N. (2004). Targeting amyloid-degrading enzymes as therapeutic strategies in neurodegeneration. *Annals of the New York Academy of Sciences*, *1035*(1), 1–20.

Turner, P. R., O'Connor, K., Tate, W. P., & Abraham, W. C. (2003). Roles of amyloid precursor protein and its fragments in regulating neural activity, plasticity and memory. *Progress in Neurobiology*, *70*(1), 1–32.

U

Unzeta, M., Esteban, G., Bolea, I., Fogel, W. A., Ramsay, R. R., Youdim, M. B. H., … Marco-Contelles, J. (2016). Multi-Target Directed Donepezil-Like Ligands for Alzheimer's Disease (Figura). *Frontiers in Neuroscience*, *10*, 205.

V

Valverde, A. M., Fabregat, I., Burks, D. J., White, M. F., & Benito, M. (2004). IRS-2 mediates the antiapoptotic effect of insulin in neonatal hepatocytes. *Hepatology (Baltimore, Md.)*, *40*(6), 1285–94.

Valverde, A. M., & González-Rodríguez, A. (2011). IRS2 and PTP1B: Two opposite modulators of hepatic insulin signalling. *Archives of Physiology and Biochemistry*, *117*(3), 105–15. http://doi.org/10.3109/13813455.2011.557386

Vandal, M., Alata, W., Tremblay, C., Rioux-Perreault, C., Salem, N., Calon, F., & Plourde, M. (2014a). Reduction in DHA transport to the brain of mice expressing human APOE4 compared to APOE2. *Journal of Neurochemistry*, *129*(3), 516–26.

Vandal, M., Bourassa, P., & Calon, F. (2015). Can insulin signaling pathways be targeted to transport Aβ out of the brain? *Frontiers in Aging Neuroscience*, *7*, 114.

Vandal, M., White, P. J., Tremblay, C., St-Amour, I., Chevrier, G., Emond, V., … Calon, F. (2014b). Insulin reverses the high-fat diet-induced increase in brain Aβ and improves memory in an animal model of Alzheimer disease. *Diabetes*, *63*(12), 4291–301.

Van Dam, D., Coen, K., & De Deyn, P. (2010). Ibuprofen modifies cognitive disease progression in an Alzheimer's mouse model. *Journal of Psychopharmacology*, *24*(3), 383–388.

Van der Flier, W. M., Pijnenburg, Y. AL, Fox, N. C., & Scheltens, P. (2011). Early-onset versus late-onset Alzheimer's disease: the case of the missing APOE ε4 allele. *The Lancet Neurology*.

Van der Heide, L. P., Ramakers, G. M. J., & Smidt, M. P. (2006). Insulin signaling in the central nervous system: learning to survive. *Progress in Neurobiology*, *79*(4), 205–21.

Van Marum, R. J. (2009). Update on the use of memantine in Alzheimer's disease. *Neuropsychiatric Disease and Treatment*, *5*, 237–47.

W

Wang, J., Gu, B. J., Masters, C. L., & Wang, Y.-J. (2017). A systemic view of Alzheimer disease — insights from amyloid-β metabolism beyond the brain. *Nature Reviews Neurology*, *13*(11), 703–703.

Wang, X., Zheng, W., Xie, J.-W., Wang, T., Wang, S.-L., Teng, W.-P., & Wang, Z.-Y. (2010). Insulin deficiency exacerbates cerebral amyloidosis and behavioral deficits in an Alzheimer transgenic mouse model. *Molecular*

Ward, A., Crean, S., Mercaldi, C. J., Collins, J. M., Boyd, D., Cook, M. N., & Arrighi, H. M. (2012). Prevalence of apolipoprotein E4 genotype and homozygotes (APOE e4/4) among patients diagnosed with Alzheimer's disease: a systematic review and meta-analysis. *Neuroepidemiology*, *38*(1), 1–17.

Watson, G. S., & Craft, S. (2004). Modulation of memory by insulin and glucose: neuropsychological observations in Alzheimer's disease. *European Journal of Pharmacology*, *490*(1–3), 97–113.

Wei, Y., Williams, J. M., Dipace, C., Sung, U., Javitch, J. A., Galli, A., & Saunders, C. (2007). Dopamine transporter activity mediates amphetamine-induced inhibition of Akt through a Ca2+/calmodulin-dependent kinase II-dependent mechanism. *Molecular Pharmacology*, *71*(3), 835–42.

Weindruch, R., Walford, R. L., Fligiel, S., & Guthrie, D. (1986). The retardation of aging in mice by dietary restriction: longevity, cancer, immunity and lifetime energy intake. *The Journal of Nutrition*, *116*(4), 641–54.

Weiner, M. W., Crane, P. K., Montine, T. J., Bennett, D. A., & Veitch, D. P. (2017). Traumatic brain injury may not increase the risk of Alzheimer disease. *Neurology*, *89*(18), 1923–1925.

Weingarten, M. D., Lockwood, A. H., Hwo, S. Y., & Kirschner, M. W. (1975). A protein factor essential for microtubule assembly. *Proceedings of the National Academy of Sciences of the United States of America*, *72*(5), 1858–62. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/1057175

Welters, A., Lammert, E., Mayatepek, E., & Meissner, T. (2017). Need for Better Diabetes Treatment: The Therapeutic Potential of NMDA Receptor Antagonists. *Klinische Padiatrie*, *229*(1), 14–20.

Weller, R. O., Subash, M., Preston, S. D., Mazanti, I., & Carare, R. O. (2008). Perivascular drainage of amyloid-beta peptides from the brain and its failure in cerebral amyloid angiopathy and Alzheimer's disease. *Brain Pathology (Zurich, Switzerland)*, *18*(2), 253–66.

Wenk, G. L. (2006). Neuropathologic changes in Alzheimer's disease: potential targets for treatment. *The Journal of Clinical Psychiatry*, *67 Suppl 3*, 3–7; quiz 23.

Whitehouse, P. J. (1986). The concept of subcortical and cortical dementia: another look. *Annals of Neurology*, *19*(1), 1–6.

Whitehouse, P. J., Price, D. L., Struble, R. G., Clark, A. W., Coyle, J. T., & Delon, M. R. (1982). Alzheimer's disease and senile dementia: loss of neurons in the basal forebrain. *Science (New York, N.Y.)*, *215*(4537), 1237–9.

Wickelgren, I. (1998). Tracking insulin to the mind. *Science (New York, N.Y.)*, *280*(5363), 517–9.

Willette, A. A., Bendlin, B. B., Starks, E. J., Birdsill, A. C., Johnson, S. C., Christian, B. T., … Asthana, S. (2015a). Association of Insulin Resistance With Cerebral Glucose Uptake in Late Middle-Aged Adults at Risk for Alzheimer Disease. *JAMA Neurology*, *72*(9), 1013–20.

Willette, A. A., Johnson, S. C., Birdsill, A. C., Sager, M. A., Christian, B., Baker, L. D., … Bendlin, B. B. (2015b). Insulin resistance predicts brain amyloid deposition in late middle-aged adults. *Alzheimer's & Dementia : The Journal of the Alzheimer's Association*, *11*(5), 504–510.e1.

Winblad, B., Engedal, K., Soininen, H., Verhey, F., Waldemar, G., Wimo, A., … Donepezil Nordic Study Group. (2001). A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD. *Neurology*, *57*(3), 489–95.

Wisniewski, H. M., & Wegiel, J. (1991). Spatial relationships between astrocytes and classical plaque components. *Neurobiology of Aging*, *12*(5), 593–600.

Withers, D. J., Gutierrez, J. S., Towery, H., Burks, D. J., Ren, J. M., Previs, S., … White, M. F. (1998). Disruption of IRS-2 causes type 2 diabetes in mice. *Nature*, *391*(6670), 900–4.

Witte, A. V., Fobker, M., Gellner, R., Knecht, S., & Floel, A. (2009). Caloric restriction improves memory in elderly humans. *Proceedings of the National Academy of Sciences*, *106*(4), 1255–1260.

Woods, S. C., & Porte, D. (1977). Relationship between plasma and cerebrospinal fluid insulin levels of dogs. *The American Journal of Physiology*, *233*(4), E331-4.

Woods, S. C., Seeley, R. J., Baskin, D. G., & Schwartz, M. W. (2003). Insulin and the blood-brain barrier. *Current Pharmaceutical Design*, *9*(10), 795–800.

X

Xiang, J. (2017). Carotid atherosclerosis promotes the progression of Alzheimer's disease: A three-year prospective study. *Experimental and Therapeutic Medicine*, *14*(2), 1321–1326.

Xiang, Y., Bu, X.-L., Liu, Y.-H., Zhu, C., Shen, L.-L., Jiao, S.-S., … Wang, Y.-J. (2015). Physiological amyloid-beta clearance in the periphery and its therapeutic potential for Alzheimer's disease. *Acta Neuropathologica*, *130*(4), 487–99.

Xu, Q., Bernardo, A., Walker, D., Kanegawa, T., Mahley, R. W., & Huang, Y. (2006). Profile and regulation of apolipoprotein E (ApoE) expression in the CNS in mice with targeting of green fluorescent protein gene to the ApoE locus. *The Journal of Neuroscience : The Official Journal of the Society for Neuroscience*, *26*(19), 4985–94.

Y

Yankner, B. A., & Mesulam, M.-M. (1991). β-Amyloid and the Pathogenesis of Alzheimer's Disease. *New England Journal of Medicine*, *325*(26), 1849–1857.

Z

Zempel, H., Thies, E., Mandelkow, E., & Mandelkow, E.-M. (2010). Abeta oligomers cause localized Ca(2+) elevation, missorting of endogenous Tau into dendrites, Tau phosphorylation, and destruction of microtubules and spines. *The Journal of Neuroscience : The Official Journal of the Society for Neuroscience*, *30*(36), 11938–50.

Zhang, B., Gaiteri, C., Bodea, L.-G., Wang, Z., McElwee, J., Podtelezhnikov, A. A., … Emilsson, V. (2013). Integrated systems approach identifies genetic nodes and networks in late-onset Alzheimer's disease. *Cell*, *153*(3), 707–20.

Zhang, F., & Jiang, L. (2015). Neuroinflammation in Alzheimer's disease. *Neuropsychiatric Disease and Treatment*, *11*, 243–56.

Zhang, Y., Thompson, R., Zhang, H., & Xu, H. (2011). APP processing in Alzheimer's disease. *Molecular Brain*, *4*(1), 3.

Zhang, Y., Zhou, B., Deng, B., Zhang, F., Wu, J., Wang, Y., … Zhai, Q. (2013). Amyloid-β induces hepatic insulin resistance in vivo via JAK2. *Diabetes*, *62*(4), 1159–66.

Zhao, J., O'Connor, T., & Vassar, R. (2011). The contribution of activated astrocytes to Aβ production: implications for Alzheimer's disease pathogenesis. *Journal of Neuroinflammation*, *8*(1), 150.

Zhao, N., Liu, C.-C., Van Ingelgom, A. J., Martens, Y. A., Linares, C., Knight, J. A., … Bu, G. (2017). Apolipoprotein E4 Impairs Neuronal Insulin Signaling by Trapping Insulin Receptor in the Endosomes. *Neuron*, *96*(1), 115–129.e5.

Zhao, W., Chen, H., Xu, H., Moore, E., Meiri, N., Quon, M. J., & Alkon, D. L. (1999). Brain insulin receptors and spatial memory. Correlated changes in gene expression, tyrosine phosphorylation, and signaling molecules in the hippocampus of water maze trained rats. *The Journal of Biological Chemistry*, *274*(49), 34893–902.

Zhao, Y., Wieman, H. L., Jacobs, S. R., & Rathmell, J. C. (2008). Chapter Twenty-Two Mechanisms and Methods in Glucose Metabolism and Cell Death. In *Methods in enzymology* (Vol. 442, pp. 439–457).

Zhao, Z., Xiang, Z., Haroutunian, V., Buxbaum, J. D., Stetka, B., & Pasinetti, G. M. (2007). Insulin degrading enzyme activity selectively decreases in the hippocampal formation of cases at high risk to develop Alzheimer's disease. *Neurobiology of Aging*, *28*(6), 824–830.